natgillin/translations-raw huggingface dataset:
Intrakraniel blødningd *
Haemorrhage intracranial d
Intrakraniel hypertension/forhøjet intrakranielt tryk
Intracranial hypertension/increased intracranial pressure
Intrakraniel hypertension/forhøjet intrakranielt tryk forekom hos 4 (0,96 %) af patienterne i de kliniske forsøg og forekom hos behandlingsnaive forsøgspersoner på 7-9 år.
Intracranial hypertension/increased intracranial pressure occurred in 4 (0.96%) of patients from the clinical trials and occurred in 7 – 9 year old treatment naïve subjects.
Intrakraniel hypotension (lækage af cerebrospinalvæske) Cerebrospinalvæske-rinoré Hovedpine
CSF rhinorrhoea Headache Hydrocephalus Subdural hygroma
Intrakranielle blødninger med dødelig udgang forekom hos 1 % (3/209) af patienterne ved brug af trametinib i kombination med dabrafenib i studiet MEK115306 og hos <1 % (3/350) af patienterne i studiet MEK116513.
Fatal intracranial haemorrhages have occurred for trametinib in combination with dabrafenib in 1% (3/209) of patients in study MEK115306 and in <1% (3/350) of patients in study MEK116513.
Intrakranielle blødninger med dødelig udgang forekom hos patienter 1 % (3/209) af patienterne i MEK115306 og hos <1 % (3/350) af patienterne i MEK116513.
Fatal intracranial haemorrhages have occurred for trametinib in combination with dabrafenib in 1% (3/209) of patients in study MEK115306 and in <1% (3/350) of patients in study MEK116513.
Intrakranielle tumorer, specielt meningiomer, var de hyppigst forekommende sekundære neoplasmer hos patienter, der havde fået strålebehandling mod hovedet ved deres første neoplasme.
Intracranial tumours, in particular meningiomas, in patients treated with radiation to the head for their first neoplasm, were the most common of these second neoplasms.
Intrakutan 15µg
Intradermal 15µg
Intrakutan anvendelse
Intradermal use
Intralæsional anvendelse
Intralesional use Intralesional use
Intramammær anvendelse
Intramammary use
Intramammær opløsning
Intramammary solution
Intramuskulær
EU/2/05/053/001
intramuskulær
injection
Intramuskulær
Intramuscular use
intramuskulær
Number
Intramuskulær
Route of Administration Intramuscular
Intramuskulær
use Intramuscular
Intramuskulær (i.m.) injektion af 1 dosis (1 ml) til grise, uafhængig af legemsvægt.
Single intramuscular (IM) injection of one dose (1 ml) to pigs, irrespective of body weight.
Intramuskulær (i.m.) og subkutan (s.c.) anvendelse
Intramuscular (IM) and subcutaneous (SC) use
Intramuskulær (i.m.) og subkutan (s.c.) anvendelse
Intramuscular (IM) and subcutaneous (SC) use.
Intramuskulær administration med 40 mkg/kg (efterfulgt af ketamin eller propofol) resulterede hyppigt i sinusbradykardi og sinusarytmi, resulterede nogle gange i førstegrads AV-blok, mens der sjældent opstod supraventrikulære præmature depolariseringer, atrielle bigeminier, sinuspauser, andengrads AV-blok eller arytmi (escape beats).
Intramuscular dosing at 40 mcg/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.
Intramuskulær anvendelse
EU/1/12/812/002
Intramuskulær anvendelse
Intramuscular injection
Intramuskulær anvendelse (i nakken).
Intramuscular use (in the neck).
Intramuskulær anvendelse Intravenøs anvendelse Subkutan anvendelse
Intramuscular use, intravenous use, subcutaneous use
Intramuskulær anvendelse Omrystes godt før brug
intramuscular use Shake well before use
Intramuskulær anvendelse Subkutan anvendelse
Intramuscular use, subcutaneous use
Intramuskulær anvendelse Subkutan anvendelse
Subcutaneous use, intramuscular use
Intramuskulær anvendelse.
Intramuscular use Vaccination schedule:
Intramuskulær anvendelse.
Intramuscular use:
Intramuskulær anvendelsee
Intramuscular use
Intramuskulær blødning (intet kompartmentsyndrom)
Intramuscular haemorrhage (no compartment syndrome)
Intramuskulær brug
Intramuscular use.
Intramuskulær brug Omrystes før brug
Intramuscular use Shake before use
Intramuskulær brug.
IM use.
Intramuskulær eller subkutan anvendelse af 0,25 til 0,5 ml, afhængigt af alder.
Intramuscular or subcutaneous use (0.25 to 0.5 ml, depending on the age).
Intramuskulær eller subkutan injektion af 0,25; 0,5 ml eller 1 ml, afhængigt af alder og art.
I.M. or S.C. injection of 0.25, 0.5 ml or 1 ml, depending on the age and species.
Intramuskulær eller subkutan injektion af 0,25;0,5 ml eller 1 ml afhængig af alder og art.
Intramuscular or subcutaneous injection of 0.25 or 0.5 ml, depending on the age.
Intramuskulær indgivelse i glutealmusklen bør undgås, da det kan medføre sub-optimalt respons.
Since intramuscular administration into the gluteal muscle could lead to a suboptimal response to the vaccine, this route should be avoided.
Intramuskulær injektion
Intramuscular injection
Intramuskulær injektion
Intramuscular use
Intramuskulær injektion bør gives langsomt og dybt i en muskel.
The IM injection should be given slowly and deeply into the muscle.
Intramuskulær, intravenøs eller subkutan anvendelse
Intramuscular use, Intravenous use, Subcutaneous use
Intramuskulært
Intramuscular use
Intramuskulært
Intramuscular use.
Intramuskulært
Route of administration
Intramuskulært flaske af “high- 500 ml 10 flasker Nul døgn
500 ml 1 bottle Zero days
Intramuskulært.
Intramuscular use.
Intranasal
Intranasal use
Intranasal/okulær, spray eller drikkevand
Intranasal/ocular, spray or drinking water
Intranasale ulcerationer
Nasal ulceration
Intraokulær anvendelse
Intraocular use
Intraoperativt Floppy-iris- syndrom
Intraoperative Floppy Iris Syndrome
Intraoperativt Floppy-iris-syndrom (IFIS):
Intraoperative Floppy Iris Syndrome (IFIS):
Intraperitoneal
Intraperitoneal use Intraperitoneal use
Intraperitoneal Injektion
injection
Intraperitoneal injektion (i.p.).
Intraperitoneal (IP) use
Intraruminal anvendelse
Intraruminal use
Intraruminalt indlæg med kontinuerlig udløsning
Continuous release intraruminal device
Intraruminalt indlæg:
Intraruminal device:
Intratekal
Intrathecal
Intratekal anvendelse
Intrathecal use.
Intratekal anvendelse har medført dødsfald.
Intrathecal administration has resulted in death.
intrathecal, dag 1
MTX 15mg intrathecal, day 1
Intrauterin fosterdød
Intrauterine foetal death
Intravaskulær administration af ioderede kontraststoffer kan føre til nyresvigt, som medfører akkumulation af metformin og risiko for laktacidose.
The intravascular administration of iodinated contrast agents may lead to renal failure resulting in metformin accumulation and a risk of lactic acidosis.
intravaskulær administration af iodholdige kontrastmidler (se pkt.
Intravascular administration of iodinated contrast agents (see section 4.4)
Intravaskulær administration af iodholdige kontrastmidler i forbindelse med radiologiske studier kan resultere i nyreinsufficiens og ophobning af metformin med risiko for laktacidose.
Intravascular administration of iodinated contrast agents in radiological studies may lead to renal failure, resulting in metformin accumulation and risk of lactic acidosis.
Intravaskulær administration af iodholdige kontrastmidler ved radiologiske studier kan føre til nyreinsufficiens.
The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure.
Intravaskulær administration af iodholdige kontraststoffer kan medføre nyresvigt med deraf følgende metformin-akkumulation med risiko for laktatacidose.
Intravascular administration of iodinated contrast media may lead to renal failure, resulting in metformin accumulation with the risk of lactic acidosis.
Intravaskulær administration af iodholdigt kontraststof ved radiologiske undersøgelser kan medføre nyreinsufficiens.
The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure.
intravaskulær administration af jodholdige kontrastmidler (se afsnit 4.4) amning.
intravascular administration of iodinated contrast agents (see section 4.4) lactation.
Intravaskulær administration af jodholdige kontraststoffer i forbindelse med radiologiske undersøgelser kan føre til nyresvigt, som er blevet associeret med laktacidose hos patienter, der får metformin.
The intravascular administration of iodinated contrast agents in radiological studies can lead to renal failure which has been associated with lactic acidosis in patients receiving metformin.
Intravaskulær administration af jodholdige kontraststoffer i forbindelse med radiologiske undersøgelser kan føre til nyresvigt, som kan medføre akkumulering af metformin og risiko for laktacidose.
The intravascular administration of iodinated contrast agents in radiological studies may lead to renal failure, resulting in metformin accumulation and a risk of lactic acidosis.
Intravaskulær administration er kontraindiceret og kan forårsage tromboembolisme.
Intravascular administration is contraindicated and may cause thromboembolism.
Intravaskulær anvendelse
Intravascular application
Intravenøs
administration
Intravenøs
Intravenous use
intravenøs
Intravenous use,
intravenøs
or intravenous
intravenøs
or intravenous use
Intravenøs
Route of
intravenøs
Route of Administration
intravenøs
Subcutaneous use
Intravenøs (80 mikrogram/kg/dag) administration af filgrastim til kaniner under organogenese var maternelt toksisk, og der blev observeret øget spontan abort, tab efter implantation og reduceret gennemsnitlig levende kuldstørrelse og fostervægt.
Intravenous (80 micrograms/kg/day) administration of filgrastim to rabbits during the period of organogenesis was maternally toxic and increased spontaneous abortion, post-implantation loss, and decreased mean live litter size and fetal weight were observed.
Intravenøs (bolus-) injektion, kun for indikationen akut STEMI
Intravenous (bolus) injection for acute STEMI indication only
Intravenøs (bolus-) injektion, kun for indikationen akut STEMI: Thorinane kan administreres sikkert med natriumchlorid injektionsvæske 9 mg/ml (0,9 %) eller 5 % glucose-injektionsvæske.
Intravenous (bolus) injection for acute STEMI indication only: Thorinane may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose in water.
Intravenøs (bolus-) injektion, kun for indikationen akut STEMI: Thorinane kan administreres sikkert med natriumchlorid injektionsvæske 9 mg/ml (0,9 %) eller 5 % glucoseinjektionsvæske.
Intravenous (bolus) injection for acute STEMI indication only: Thorinane may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose in water.
Intravenøs (bolus-) injektion, kun for indikationen akut STEMI: Thorinane kan administreres sikkert med natriumchlorid injektionsvæske 9 mg/ml (0,9 %) eller 5 % glukose i vand.
Intravenous (bolus) injection for acute STEMI indication only: Thorinane may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose in water.
Intravenøs (bolus-) injektion, kun for indikationen akut STEMI: Thorinane kan administreres sikkert med natriumchlorid-injektionsvæske 9 mg/ml (0,9 %) eller 5 % glucose-injektionsvæske.
Intravenous (bolus) injection for acute STEMI indication only: Thorinane may be safely administered with sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose in water.
Intravenøs (bolus-) injektion, kun ved indikationen akut STEMI
Intravenous (bolus) injection for acute STEMI indication only
intravenøs 2 timer
intravenous 2 hr
intravenøs 2 timer
Starting Dose
intravenøs 22 timer
m2 intravenous 22 hr
Intravenøs administration
Intravenous administration:
Intravenøs administration (første dosis for patienter, der kun har STEMI)
Intravenous administration (first dose in patients with STEMI only)
Intravenøs administration af 14C-mærket isavuconazoniumsulfat til diende rotter medførte udskillelse af radioaktivt mærket stof i mælken.
Intravenous administration of 14C-labelled isavuconazonium sulfate to lactating rats resulted in the recovery of radiolabel in the milk.
Intravenøs administration af bivalirudin viser målbar antikoagulation inden for minutter.
Intravenous administration of bivalirudin produces measurable anticoagulation within minutes.
Intravenøs administration af doser på op til 4.000 mg fortyndet i 100 ml 0,9 % natriumchlorid infunderet over 15 minutter og doser op til 2.500 mg fortyndet i 100 ml 0,9 % natriumchlorid infunderet over 5 minutter blev evalueret.
The intravenous administration of doses up to 4,000 mg diluted in 100 ml of 0.9 % sodium chloride infused over 15 minutes and doses up to 2,500 mg diluted in 100 ml of 0.9 % sodium chloride infused over 5 minutes was evaluated.
Intravenøs administration af insulin
Intravenous administration of insulin:
Intravenøs administration skal gives direkte i en eksisterende intravenøs adgang eller ved anvendelse af en lille (25 eller 50 ml) minipose med 0,9 % saltopløsning.
Intravenous administration should be through an existing intravenous line either directly or using a small volume (25 or 50ml) 0.9% saline minibag.
Intravenøs administration skal helst foregå ved løbende intravenøs infusion over 20-30 minutter (se pkt.
Intravenous administration occurs preferably through a running intravenous infusion over 20-30 minutes (see section 6.6).
Intravenøs administration som to på hinanden følgende infusioner, der hver især indgives over 5-10 min., eller som bolusinjektion.
Intravenous administration as two consecutive infusions over 5 to 10 min each or as bolus injections
Intravenøs anvendelse
(concentration)
Intravenøs anvendelse
For intravenous use
Intravenøs anvendelse
I.V. use.
intravenøs anvendelse
intravenous use Subcutaneous use
Intravenøs anvendelse
Route of administration
Intravenøs anvendelse
Route of administration Intravenous use
Intravenøs anvendelse (hunde) Intramuskulær anvendelse (hunde og katte)
Intravenous use (dogs), Intramuscular use (dogs and cats)
Intravenøs anvendelse (kvæg og heste), subkutan anvendelse (kvæg)
Intravenous use (cattle and horses), subcutaneous use (cattle)
Intravenøs anvendelse (kvæg og heste), subkutan anvendelse (kvæg)
Route of administration
Intravenøs anvendelse efter opblanding
Intravenous use after reconstitution
Intravenøs anvendelse efter rekonstitution og fortynding.
Intravenous use after reconstitution and dilution
Intravenøs anvendelse eller Subkutan anvendelse
Subcutaneous or intravenous use
Intravenøs anvendelse i.v.
Intravenous use IV
Intravenøs anvendelse Intravenøs
Intravenous use
Intravenøs anvendelse Intravenøs
Intravenous use Intravenous use Intravenous use
Intravenøs anvendelse Intravenøs anvendelse
for Intravenous use
Intravenøs anvendelse Klinisk virkning
Intravenous use Clinical efficacy
Intravenøs anvendelse Kun til engangsbrug.
Intravenous use For single use only
Intravenøs anvendelse Kun til engangsbrug.
Intravenous use For single use only.
Intravenøs anvendelse pulver: hætteglas,
Intravenous use powder: vial (glass); solvent: vial (glass)
Intravenøs anvendelse Subkutan anvendelse
Intravenous use, Subcutaneous use
Intravenøs anvendelse, efter fortynding med 5 % (50 mg/ml) glucose infusionsvæske.
Intravenous use, following dilution in 5% (50 mg/ml) glucose solution for infusion.
Intravenøs anvendelse, kun til engangsbrug Skal fortyndes før anvendelse
Intravenous use, single use only
Intravenøs anvendelse, Subkutan anvendelse
Intravenous use,
Intravenøs anvendelse.
For intravenous use.
Intravenøs behandling med den indledende bolusinjektion af atosiban 6,75 mg/0,9 ml injektionsvæske, opløsning (se produktresume for dette produkt) skal påbegyndes hurtigst muligt efter diagnosen for tidlig fødsel er blevet stillet.
Intravenous therapy using the initial bolus injection of atosiban 6.75 mg/0.9 ml, solution for injection (see Summary of Product Characteristics of this product) should be started as soon as possible after diagnosis of pre-term labour.
intravenøs beroligende medicin - benzodiazepiner (f.eks. alprazolam, midazolam, triazolam)
intravenous sedatives - benzodiazepines (e.g., alprazolam, midazolam, triazolam)
Intravenøs bolus administration med insulin glulisin resulterede i en højere systemisk indvirkning sammenlignet med subkutan injektion med en Cmax ca.
Intravenous bolus administration of insulin glulisine resulted in a higher systemic exposure when compared to subcutaneous injection, with a Cmax approximately
intravenøs bolus,
intravenous bolus,
Intravenøs bolus- administration med insulin glulisin resulterede i en højere systemisk indvirkning sammenlignet med subkutan injektion med en Cmax ca.
Intravenous bolus administration of insulin glulisine resulted in a higher systemic exposure when compared to subcutaneous injection, with a Cmax approximately
Intravenøs bolus-administration med insulin glulisin resulterede i en højere systemisk indvirkning sammenlignet med subkutan injektion med en Cmax ca.
Intravenous bolus administration of insulin glulisine resulted in a higher systemic exposure when compared to subcutaneous injection, with a Cmax approximately
Intravenøs bolus: brivaracetam kan administreres som intravenøs bolus uden fortynding.
Intravenous bolus: brivaracetam may be administered as an intravenous bolus without dilution.
Intravenøs bolus: kan administreres direkte uden fortynding
Intravenous bolus: may be administered directly without dilution
Intravenøs bolusinjektion kan gives hurtigt og direkte ind i en vene eller i et eksisterende drop.
The IV bolus injection may be given rapidly and directly into a vein or into an existing IV line.
Intravenøs bolusinjektion ved non-lineær kontrastbilledteknik ved hvile og stress:
Bolus intravenous injection using non-linear contrast imaging technique at rest and stress:
Intravenøs brug efter rekonstitution of opløsning
Intravenous used after reconstitution and dilution
Intravenøs brug.
Intravenous use
Intravenøs dexamethason 20 mg bør administreres 1 time inden initiering af hver cyklus med BLINCYTO-behandling.
Dexamethasone 20 mg intravenous should be administered 1 hour prior to initiation of each cycle of BLINCYTO therapy.
intravenøs docetaxel – 75 mg/m2 som intravenøs infusion over 1 time, administreret hver 3. uge i 6 serier (dag 2 i serie 1, derefter dag 1 i hver af de efterfølgende serier)
intravenous docetaxel - 75 mg/m2 as an intravenous infusion over 1 hour, given every 3 weeks for 6 cycles (day 2 of cycle 1, then day 1 of each subsequent cycle)
Intravenøs eller intramuskulær anvendelse
Intravenous or intramuscular use
Intravenøs eller subkutan anvendelse Læs indlægssedlen inden brug.
For intravenous or subcutaneous use Read the package leaflet before use.
Intravenøs eller subkutan anvendelse.
Intravenous or subcutaneous use.
Intravenøs eller subkutan væsketerapi under anæstesi bør overvejes i de tilfælde, hvor anæstesi kan medføre en forøget risiko for dyret (f.eks. ved gamle dyr).
In animals at anaesthetic risk (e.g. aged animals) intravenous or subcutaneaous fluid therapy during anaesthesia should be taken into consideration.
Intravenøs eller subkutan væsketerapi under anæstesi bør overvejes i de tilfælde, hvor anæstesi kan medføre en forøget risiko for dyret (f.eks. ved gamle dyr).
In animals at anaesthetic risk (e.g., aged animals), intravenous or subcutaneous fluid therapy during anaesthesia should be taken into consideration.
intravenøs erythromycin (et antibiotikum)
intravenous erythromycin (an antibiotic)
Intravenøs formulering
Herceptin Intravenous
Intravenøs hætteglas (glas)
Intravenous use
intravenøs infusion
intravenous infusion
Intravenøs infusion
Intravenous infusion administration:
Intravenøs infusion (over 10 minutter) eller ved oral administration
Intravenous infusion (over 10 minutes) or by oral administration
Intravenøs infusion (over 30 minutter)
Intravenous infusion (over 30 minutes)
Intravenøs infusion af Herceptin bør administreres af sundhedspersonale, som er forberedt på at håndtere anafylaksi, og nødudstyr skal være tilgængeligt.
Herceptin intravenous infusion should be administered by a health- care provider prepared to manage anaphylaxis and an emergency kit should be available.
Intravenøs infusion efter fortynding Læs indlægssedlen inden brug
Intravenous use, for infusion after dilution Read the package leaflet before use
Intravenøs infusion med 5 mg/kg efterfulgt af yderligere infusionsdoser på 5 mg/kg 2 og 6 uger efter den første infusion, og herefter hver 8. uge.
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
Intravenøs infusion: brivaracetam kan fortyndes i en kompatibel fortyndingsvæske og administreres som intravenøs infusion over 15 minutter (se pkt.
Intravenous infusion: brivaracetam may be diluted in a compatible diluent and administered as a 15-minute intravenous infusion (see section 6.6).
Intravenøs infusion: kan administreres over 15 minutter i en kompatibel fortyndingsvæske
Intravenous infusion: may be administered over 15 minutes in a compatible diluent
Intravenøs infusionsvæske med Oncaspar gives sædvanligvis i løbet af 1 til 2 timer med 100 ml natriumchlorid, 9 mg/ml (0,9 %), som injektionsvæske, opløsning eller med en dextroseopløsning på 5 % sammen men en igangværende infusion.
Intravenous infusion of Oncaspar is usually given over a period of 1 to 2 hours in 100 ml sodium chloride 9 mg/ml (0.9%) solution for injection or 5% glucose solution together with an already-running infusion.
Intravenøs injektion af insulin bør udføres efter normal klinisk praksis for intravenøs injektion, f.eks. i form af en intravenøs bolus eller et infusionssystem.
Intravenous injection of insulin lispro should be carried out following normal clinical practise for intravenous injections, for example by an intravenous bolus or by an infusion system.
Intravenøs injektion, subkutan injektion
Intravenous use, subcutaneous use
Intravenøs injektion/infusion.
Intravenous use.
Intravenøs injektion:
Intravenous administration:
Intravenøs midazolam 2 mg blev givet 1 time efter oral administation af en enkelt dosis EMEND 125 mg.
Intravenous 2 mg midazolam was given 1 hour after oral administration of a single dose of EMEND 125 mg.
Intravenøs midazolam 2 mg blev givet 1 time efter oral administration af en enkelt dosis EMEND 125 mg.
Intravenous 2 mg midazolam was given 1 hour after oral administration of a single dose of EMEND 125 mg.
Intravenøs ofatumumab er blevet forbundet med infusionsreaktioner.
Intravenous ofatumumab has been associated with infusion reactions.
Intravenøs og subkutan
intravenous use
Intravenøs og subkutan
Subcutaneous or
Intravenøs og subkutan
Subcutaneous or intravenous use
Intravenøs og subkutan administration til aber resulterede i den forventede depletion af B-celler i perifert og lymfoidt væv uden relaterede toksikologiske fund.
Intravenous and subcutaneous administration to monkeys resulted in the expected depletion of peripheral and lymphoid tissue B cell counts with no associated toxicological findings.
intravenøs paclitaxel – 80 mg/m2 som kontinuerlig intravenøs infusion, administreret hver uge i 12 uger.
intravenous paclitaxel - 80 mg/m2 as a continuous intravenous infusion, given every week for 12 weeks.
intravenøs paclitaxel – 80 mg/m2 som kontinuerlig intravenøs-infusion, administreret hver uge i 12 uger.
intravenous paclitaxel - 80 mg/m2 as a continuous intravenous infusion, given every week for 12 weeks.
Intravenøs slange af polyolefin, non-DEHP til PVC eller EVA med et sterilt, pyrogenfrit integreret 0,2 μm filter med lav proteinbinding
Polyolefin, PVC non-DEHP, or EVA intravenous tubing with a sterile, non-pyrogenic, low protein-binding 0.2 micrometre in-line filter;
Intravenøs slange af polyolefin, non-DEHP til PVC eller EVA med et sterilt, pyrogenfrit integreret 0,2 μm filter med lav proteinbinding.
Polyolefin, PVC non-DEHP, or EVA intravenous tubing with a sterile, non-pyrogenic, low protein-binding 0.2 micrometre in-line filter.